These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24102896)

  • 1. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.
    Rhodes T; Norquist JM; Sisk CM; McQuarrie K; Trovato A; Liao J; Miller T; Maccubbin D; Watson DJ
    Int J Clin Pract; 2013 Dec; 67(12):1238-46. PubMed ID: 24102896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a questionnaire to assess niacin-induced cutaneous flushing.
    Norquist JM; Watson DJ; Yu Q; Paolini JF; McQuarrie K; Santanello NC
    Curr Med Res Opin; 2007 Jul; 23(7):1549-60. PubMed ID: 17559750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of laropiprant on niacin-induced flushing.
    Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB
    Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial.
    Paolini JF; Mitchel YB; Reyes R; Thompson-Bell S; Yu Q; Lai E; Watson DJ; Norquist JM; Sisk CM; Bays HE
    Int J Clin Pract; 2008 Jun; 62(6):896-904. PubMed ID: 18410350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
    Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D
    Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
    Kamal-Bahl S; Watson DJ; Ambegaonkar BM
    Clin Ther; 2009 Jan; 31(1):130-40. PubMed ID: 19243714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
    Thakkar RB; Kashyap ML; Lewin AJ; Krause SL; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2009; 9(2):69-79. PubMed ID: 19331435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.
    Kawata AK; Revicki DA; Thakkar R; Jiang P; Krause S; Davidson MH; Punzi HA; Padley RJ
    Clin Drug Investig; 2009; 29(4):215-29. PubMed ID: 19301936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; Shamp TR
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
    Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
    Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; McGovern ME; Kissling CJ
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):78-88. PubMed ID: 17323787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apple pectin for the reduction of niacin-induced flushing.
    Moriarty PM; Backes J; Dutton JA; He J; Ruisinger JF; Schmelzle K
    J Clin Lipidol; 2013; 7(2):140-6. PubMed ID: 23415433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.